Previous 10 | Next 10 |
-- U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway -- -- Commenced Launch of VAZKEPA® (icosapent ethyl) in England & Wales Mid-October As Planned – -- Obtained Positive Scientific Assessment for Reimbu...
Amarin ( NASDAQ: AMRN ) is scheduled to announce Q3 earnings results on Thursday, October 27th, before market open. The consensus EPS Estimate is -$0.06 (vs. -$0.03 last year) and the consensus Revenue Estimate is $87.49M (-38.4% Y/Y). Over the last 2 years, AMRN has...
Lars Ekman and Patrick O’Sullivan to Retire from Amarin Board at year-end New Independent Directors Bring Significant International Experience in Healthcare and Finance Seventy-five Percent New Independent Directors Appointed Over Last Twelve Months Am...
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s third quarter 2022 financial results on Th...
Summary After the generic infringement debacle, Amarin transitioned from a growth stock to a turnaround play. I dropped the company from coverage after the former CEO John Thero jumped ship. Nevertheless, there are ongoing changes that, if fruitful, can turn around Amarin. ...
Update 4:30pm : Adds Amarin response. Amarin Corp. ( NASDAQ: AMRN ) rose 2.1% after activist Sarissa Capital said it has started the process for calling a special meeting to replace some board members. "We hope that this process will ultimately be unnecessary a...
-- Highlights Active Board Refreshment Process -- -- Amarin Has Engaged Proactively and Frequently with Sarissa -- DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today issued the following statement in response...
Amarin Corp. ( NASDAQ: AMRN ) rose 2.1% after activist Sarissa Capital said it has started the process for calling a special meeting to to replace some board members. "We hope that this process will ultimately be unnecessary and that the board will act swiftly to appoi...
Sarissa believes Amarin risks destroying additional shareholder value unless Sarissa representatives are immediately added to the board Amarin board’s governance process lacks urgency and disregards shareholder vote at annual meeting Sarissa Capital Management...
Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...